SML-8-73-1
SML-8-73-1 is a nucleotide-based KRASG12C inhibitor. SML-8-73-1 can be used for the study of non-small cell lung cancer (NSCLC).
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1536470-92-4
- Fòrmula: C14H21ClN6O12P2
- Peso molecular:562.75
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
IC50 & Target
|
KRAS(G12C) |
In Vitro
SML-8-73-1 (2.5 μM, 2 h) can specifically and covalently modify KRASG12C, but not KRASWT[1].
SML-8-73-1 (2.5 μM, 2 h) can effectively bind to KRASG12C at high intracellular nucleotide concentrations, overcoming competitive inhibition[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 1536470-92-4
-
Peso molecular 562.75
-
Fòrmula C14H21ClN6O12P2
-
SMILES
O=C1C(N=CN2[C@@H]3O[C@H](COP(OP(OCCNC(CCl)=O)(O)=O)(O)=O)[C@@H](O)[C@H]3O)=C2N=C(N)N1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Lim SM, et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl. 2014 Jan 3;53(1):199-204. [Content Brief]
[2]. Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021 Nov 15;6(1):386. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SML-8-73-1 Related Classifications
HY-19315 Related Classifications
Powered by Bioz